Regenerative medicine company Avita Medical (ASX:AVH) has been granted a trading halt this morning with its shares placed in pre-open.
Avita requested the halt after it received a regulatory update.
Avita develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects.
The company’s patented and proprietary tissue‐culture, collection and application technology provides treatment solutions derived from a patient’s own skin.
The halt will remain in place until the opening of trade on Wednesday 17th September 2014, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.